These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23449717)

  • 1. Different intravitreal properties of three triamcinolone formulations and their possible impact on retina practice.
    Chen H; Sun S; Li J; Du W; Zhao C; Hou J; Xu Y; Cheng L
    Invest Ophthalmol Vis Sci; 2013 Mar; 54(3):2178-85. PubMed ID: 23449717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the differences in pharmacokinetics and pharmacodynamics between four distinct formulations of triamcinolone acetonide.
    Zacharias LC; Lin T; Migon R; Ghosn C; Orilla W; Feldmann B; Ruiz G; Li Y; Burke J; Kuppermann BD
    Retina; 2013 Mar; 33(3):522-31. PubMed ID: 22990317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model.
    Chen M; Li X; Liu J; Han Y; Cheng L
    J Control Release; 2015 Apr; 203():109-17. PubMed ID: 25700623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Further characterization of ocular safety profile of commercially available preserved and preservative-free triamcinolone acetonide.
    Li Y; Chen H; Hou J; Zhang Y; Li G; Gu X; Luo L; Shen H; Qu J; Cheng L
    Retina; 2012 Feb; 32(2):364-74. PubMed ID: 21909054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Preservative-free triamcinolone versus purified triamcinolone preparations].
    Spitzer MS; Ziemssen F; Yörük E; Bartz-Schmidt KU; Schultheiss M; Szurman P
    Klin Monbl Augenheilkd; 2011 Jul; 228(7):626-30. PubMed ID: 21117016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular distribution and toxicity of intravitreal injection of triamcinolone acetonide in normal equine eyes.
    Yi NY; Davis JL; Salmon JH; Gilger BC
    Vet Ophthalmol; 2008 Sep; 11 Suppl 1():15-9. PubMed ID: 19046265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitreous pharmacokinetics and retinal safety of intravitreal preserved versus non-preserved triamcinolone acetonide in rabbit eyes.
    Oliveira RC; Messias A; Siqueira RC; Bonini-Filho MA; Haddad A; Damico FM; Maia-Filho A; Crispim PT; Saliba JB; Ribeiro JA; Scott IU; Cunha AS; Jorge R
    Curr Eye Res; 2012 Jan; 37(1):55-61. PubMed ID: 22029458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraocular concentration of triamcinolone acetonide after intravitreal injection in the rabbit eye.
    Kamppeter BA; Cej A; Jonas JB
    Ophthalmology; 2008 Aug; 115(8):1372-5. PubMed ID: 18355920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retinal toxicity of intravitreal kenalog in albino rabbits.
    Lang Y; Zemel E; Miller B; Perlman I
    Retina; 2007; 27(6):778-88. PubMed ID: 17621190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocular pharmacokinetics profile of different indomethacin topical formulations.
    Bucolo C; Melilli B; Piazza C; Zurria M; Drago F
    J Ocul Pharmacol Ther; 2011 Dec; 27(6):571-6. PubMed ID: 22059858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Characteristic of ocular safety profile of triamcinolone made in China].
    Lan B; Hou J; Zhao C; Sun S; Li J; Cheng L
    Zhonghua Yan Ke Za Zhi; 2014 Jul; 50(7):529-35. PubMed ID: 25312463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide.
    Robinson MR; Lee SS; Kim H; Kim S; Lutz RJ; Galban C; Bungay PM; Yuan P; Wang NS; Kim J; Csaky KG
    Exp Eye Res; 2006 Mar; 82(3):479-87. PubMed ID: 16168412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma.
    Buitrago E; Del Sole MJ; Torbidoni A; Fandino A; Asprea M; Croxatto JO; Chantada GL; Bramuglia GF; Schaiquevich P
    Exp Eye Res; 2013 Mar; 108():103-9. PubMed ID: 23333535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of triamcinolone acetonide in ocular tissues after intravitreal injection to rabbit using liquid chromatography-tandem mass spectrometry.
    Zhang SQ
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Mar; 879(7-8):548-52. PubMed ID: 21296037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection.
    Beer PM; Bakri SJ; Singh RJ; Liu W; Peters GB; Miller M
    Ophthalmology; 2003 Apr; 110(4):681-6. PubMed ID: 12689886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninfectious endophthalmitis occurring after intravitreal triesence injection.
    Bakri SJ; Edwards AO; Couch SM
    Retin Cases Brief Rep; 2009; 3(3):316-8. PubMed ID: 25389596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clearance of intravitreal voriconazole.
    Shen YC; Wang MY; Wang CY; Tsai TC; Tsai HY; Lee YF; Wei LC
    Invest Ophthalmol Vis Sci; 2007 May; 48(5):2238-41. PubMed ID: 17460285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation, characterization, and in vivo evaluation of triamcinolone acetonide microspheres after intravitreal administration.
    Zarei-Ghanavati S; Malaekeh-Nikouei B; Pourmazar R; Seyedi S
    J Ocul Pharmacol Ther; 2012 Oct; 28(5):502-6. PubMed ID: 22537291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraocular availability of triamcinolone acetonide after intravitreal injection.
    Jonas JB
    Am J Ophthalmol; 2004 Mar; 137(3):560-2. PubMed ID: 15013884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocular silicon distribution and clearance following intravitreal injection of porous silicon microparticles.
    Nieto A; Hou H; Sailor MJ; Freeman WR; Cheng L
    Exp Eye Res; 2013 Nov; 116():161-8. PubMed ID: 24036388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.